Articles tagged with Colorectal Cancer
Research estimates a lifetime cancer risk of 0.14% and 0.022% from virtual colonoscopy, with the colon, stomach, and bladder being at greatest risk. While low radiation risks are promising, practical issues such as bowel preparation and patient compliance remain to be addressed.
Researchers found that African Americans and Native Americans are more likely to be diagnosed with advanced disease and die of their disease compared to Asian Americans and non-Hispanic whites. The study highlights the importance of considering heterogeneity within broad racial/ethnic categories when evaluating cancer risks.
A new study found that anal cancer precursors are common among HIV-negative, sexually active men who have sex with men, regardless of age. The study also identified risk factors for these precancerous lesions, including HPV infection and having multiple male sex partners.
A phase I study has shown early promise for a cancer-killing virus targeting colorectal cancer. The virus, NV1020, selectively kills cancer cells while sparing normal tissue, leading to improved CEA reductions and median survival times of up to 23 months.
Researchers found that a diet high in vitamin B6 may reduce the risk of colorectal cancer in women, particularly those who consume alcohol. The study suggests that maintaining a normal or high intake of vitamin B6 can help prevent the development of cancerous polyps in the colon.
The UK Appalachia Community Cancer Network will focus on prevention and early detection of specific cancers with high incidence rates in the region. The network builds on the progress made by a previous program and aims to address the high cancer burden in Appalachian communities.
Studies show that smoking, red meat intake, and alcohol use increase the risk of serious gastrointestinal cancers. Patients who used tobacco and/or alcohol were diagnosed three to five years earlier on average than those who never smoked or drank.
A study found that cetuximab, an Erbitux-based treatment, helped shrink tumors and extend survival in patients with metastatic colorectal cancer who had previously failed treatment. The typical patient survived 6.6 months after treatment.
Panitumumab demonstrated a median survival time of 37.6 weeks and tumor response for 29% of patients with mCRC. The study confirmed safety and efficacy findings previously reported, suggesting panitumumab as an additional treatment option for managing the disease.
New fluorescent technology, Onco-LIFE, improves colonoscopy's diagnostic capability by increasing tumor detection and accuracy. The Aer-O-Scope device offers a self-propelling, self-navigating option for colon cancer screening, potentially reducing discomfort and improving success rates.
The American Gastroenterological Association emphasizes the importance of standard colonoscopy as the most cost-effective option for an accurate diagnosis of colon cancer. Meanwhile, researchers have identified factors that increase the rate of missed diagnoses during colonoscopies, including patient age, gender, and location of tumor....
A Mayo Clinic-led study has found a genetic biomarker that can predict which patients are most likely to experience unwanted side effects from oxaliplatin-based chemotherapy regimens. This biomarker could enable early identification and alternative treatments for patients at risk of nerve damage.
A meta-analysis of 35 studies found CT colonography to have a high sensitivity and specificity for detecting polyps and colorectal cancer, making it a promising alternative for screening. The study's findings suggest that CT colonography could increase patient compliance and improve early detection rates.
Researchers from Thomas Jefferson University have successfully created plant factories that produce antibodies against tumor cells, offering a potential alternative to expensive and traditional methods. The plant-made antibodies show similar effectiveness in inhibiting tumor growth as mammalian-made monoclonal antibodies.
A Northwestern Memorial HealthCare study identified a gene variant TGFBR1*6A associated with a high risk of colorectal cancer. The variant was found to be more prevalent among patients without a mutation in other genes, suggesting its potent contribution to familial cases.
Researchers found a modest increase in colorectal cancer incidence in families without MMR deficiency, but no increased risk for other malignancies. These findings allow clinicians to provide more accurate and lower-risk information to affected families.
The revised Bethesda guidelines effectively identify patients at risk for hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome. A study of 1,222 patients found that these guidelines are the most effective way to detect MSH2 or MLH1 gene carriers.
Virtual colonoscopy is effective in detecting large colorectal polyps and masses, but is less sensitive for smaller ones. The review found no direct evidence on the effect of screening methods on cancer incidence or death prevention.
Researchers say virtual colonoscopy may be the answer to improving screening rates for colorectal cancer. The non-invasive test is highly sensitive and specific, while also being convenient and cost-effective, with minimal risk of side effects.
Researchers found that certain dietary chemical compounds, such as PCBs, increase the risk of colon cancer by causing genetic alterations in genes like K-Ras and p53. The study suggests that diet plays a significant role in colorectal cancer development, with fat, red meat, and excessive calorie consumption being major risk factors.
The study found a significant increase in patients becoming up-to-date with screening recommendations and tests, from 38.7% to 56.1%, and the use of posters and brochures about CRC screening increased from 20.5% to 69.3%. Direct discussion of screening was the most common method for educating patients.
A new syndrome of colorectal cancer has been identified, characterized by frequent mutations in the BRAF oncogene and DNA methylation. This inherited form of cancer often develops in previously harmless polyps and can occur in young individuals, emphasizing the importance of early detection and prevention.
A new genetic test has been found to detect mutations that conventional DNA tests may miss, particularly large genomic deletions. This test, known as conversion analysis, increased the diagnostic yield of deleterious mutations by 56%. The study suggests this method could be a valuable addition to current genetic testing strategies.
A cohort study in Japan found that daily coffee consumption was associated with a reduced risk of hepatocellular carcinoma (HCC). In contrast, no association was found between coffee consumption and colorectal cancer incidence. The authors suggest further studies to confirm these findings.
A study published in the Journal of the National Cancer Institute found that increases in managed care market share were not associated with improved quality of care for cancer patients, except for a specific blood test. The authors conclude that expansion of managed care may not improve quality of care for all patients.
A study of 45,354 US women found that high calcium intake reduced the risk of colorectal cancer by 26%. Consuming a diet rich in calcium, even lower than current recommended daily allowance, is a safe and effective way for women to guard themselves against colorectal cancer.
Researchers found that elevated levels of ávâ6 expression in colon carcinoma cells are associated with reduced patient survival. The molecule is identified as an independent prognostic marker for colorectal cancer and predictive of early-stage disease outcomes.
The American Gastroenterological Association recommends colonoscopy as the preferred screening method for colorectal cancer due to its ability to detect and remove precancerous polyps. In-office fecal occult blood tests are not recommended as a standalone screening test, but can be used in conjunction with flexible sigmoidoscopy.
Current FOBT screening recommendations are being reexamined due to low test accuracy and non-compliance. A study of 3,121 people found that single office-based FOBT tests missed advanced precancerous lesions 95% of the time.
A recent study published in JAMA found that long-term high consumption of red and processed meat is associated with an increased risk of colon cancer. The study, which included over 148,000 adults, also found that poultry and fish consumption was inversely linked to colon cancer risk.
Fewer than half of patients had received at least one screening test more than six months prior to diagnosis. Patients with a history of screening had earlier stage and presumably more treatable disease, highlighting the underuse of colorectal procedures in clinical practice.
A new stool DNA test has been found to detect a significant proportion of colorectal cancers, potentially overcoming barriers to screening among unwilling individuals. The test, which analyzes tumor-specific DNA, detected 52% of cancers in average-risk asymptomatic individuals.
The NIH has suspended the use of celecoxib, a COX-2 inhibitor, in its large-scale cancer prevention trial after finding a two-fold increased risk of cardiovascular toxicities. The decision was made following a September 2004 report that highlighted concerns over the safety of rofecoxib, another COX-2 inhibitor.
A study estimates that 41 million Americans are eligible for colorectal cancer screening, but only a fraction have received it. The capacity for screening tests like flexible sigmoidoscopy and colonoscopy is limited, with colonoscopies being the most expensive option.
CT colonography offers improved accuracy and convenience for colorectal cancer screening, but challenges remain in standardization, patient preparation, and interpretation of results. Standardization and training are necessary for widespread adoption.
A recent study has revealed a genetic link to colon cancer, identifying the MutY human homologue (MYH) gene as a risk factor. The research found that children of MYH gene carriers have a higher risk of developing the disease, with a 1:2 ratio.
Researchers developed a method combining CYP3A4 phenotyping with UGT1A1 genotyping to optimize irinotecan chemotherapy. Greater height, obesity, and lower physical activity levels are linked to increased endometrial cancer risk.
Increased use of virtual colonoscopy is expected to lead to a decrease in traditional colonoscopies due to improved detection rates. Virtual colonoscopy without bowel preparation has been found to be as effective as traditional colonoscopy in detecting colorectal polyps, increasing patient compliance and potential screening rates.
A new study suggests that virtual colonoscopy may be associated with a higher risk of colorectal cancer deaths and procedure-related deaths. The model attributes this higher rate of mortality to declining sensitivity when the two tests are performed, as well as increased radiation exposure.
A new study identifies 38 patients under 50 with colorectal cancer, half with family history. The research concludes that African-Americans and Hispanics should begin screening at age 40 regardless of family history.
A UCLA study of 22,343 adults aged 50+ in California found that 54% had a recent CRC test, with disparities seen among Latinos, women, and those without insurance or continuity of care. Improving access to screening through policies and education programs can help address these gaps.
Researchers used a mouse model to show that TGF-b production in tumor-infiltrating T lymphocytes is crucial for colon cancer progression. Inhibition of IL-6 trans-signaling prevented tumor growth, suggesting novel therapeutic approaches for colorectal cancer.
Allopurinol, commonly used for gout, was found to significantly reduce the risk of colorectal cancer in patients taking the medication for at least five years. The study analyzed data from 1,781 patients and showed a notable reduction in risk.
A retrospective cohort study of 24,918 patients with type 2 diabetes found those on more than three years of insulin therapy have a significantly higher risk of developing colorectal cancer. The study's lead author hopes the findings will lead to more effective cancer prevention efforts.
A new targeted cancer treatment, cetuximab, has shown improved response rates and survival times in advanced colorectal cancer patients who develop an acne-like rash. The study found that the severity of the rash correlated with better tumour responses and longer median survival times.
Researchers at Vanderbilt University Medical Center have identified a new potential target for preventing colon cancer: the PPARdelta gene. By 'knocking out' this gene in mice, they found that polyp development was inhibited, providing a promising avenue for safer prevention methods.
The American College of Gastroenterology states that colonoscopy is the best and gold-standard test for colorectal cancer screening and prevention. It prevents about 80 percent of colorectal cancers from developing by removing precancerous polyps, while CT colonography has shown poor results in comparison.
Virtual colonoscopy has shown promise as a colorectal cancer screening option, with limitations in detecting flat polyps and varying results in clinical trials. Further research is needed to determine the optimal size for removing small growths and standardizing test performance.
A recent study found that cancer survivors experience significant long-term burdens, including lower quality of life and lost productivity, persisting even beyond 10 years after diagnosis. The burden varies by cancer type, with those diagnosed with shorter-survival cancers reporting greater impacts.
The American Gastroenterological Association disputes the validity of a recent study suggesting that too many surveillance colonoscopies are being performed. The study, published in Annals of Internal Medicine, highlights the importance of determining the clinical significance of small polyps and notes the need for further research to ...
Physicians often recommend more frequent surveillance colonoscopies than recommended guidelines, citing clinical evidence and personal factors as influential. This may lead to unnecessary procedures, affecting quality of care and resource utilization.
A national study led by UC Davis researchers found that surveillance colonoscopies are performed more frequently than necessary, with 24% of gastroenterologists recommending unnecessary procedures. The study suggests that implementation of clinical guidelines can help optimize patient care and reduce healthcare burden.
A study found that physical symptoms, such as shortness of breath and weakness, predict cancer prognosis. Physical health-related quality of life (hrQoL) factors were stronger predictors of survival than psychosocial factors.
A new phase 2 study shows that combining cetuximab with irinotecan can resensitize tumors resistant to irinotecan, offering patients a new treatment option. The study's modest benefits in stopping cancer growth and improving patient response are seen as a step forward in treating colorectal cancer.
Researchers engineered a decoy Met receptor that successfully competes for HGF binding, inhibiting tumor growth and survival. The Sema domain of the Met receptor is also necessary for activation, offering a new therapeutic target for cancer treatment.
Researchers found that higher milk consumption and total calcium intake were associated with a reduced risk of colorectal cancer. The risk decreased with increasing milk consumption, particularly cancers of the distal colon and rectum.
A recent study found that calcium supplementation can slightly decrease the risk of all types of colorectal polyps, with a greater effect on advanced lesions. Additionally, a diet high in fiber and low in fat may enhance this preventive effect.
Researchers found that calcium supplementation slightly decreases the risk of all types of colorectal polyps, with a greater effect on advanced lesions. A diet high in fiber and low in fat also shows promise in increasing the preventive effect of calcium.
A new study demonstrates that Xeloda reduces the risk of colon cancer recurrence (relapse-free survival) by 14% compared to i.v. 5-FU/LV after surgery. The global trial, X-ACT, met its primary endpoint and offers new hope for patients with early stage colon cancer.
A Phase III trial found that CAMPTOSAR combinations with select targeted agents improve survival for MCRC patients. The combination of Avastin and IFL yields an average survival of 25.1 months compared to 15.8 months with IFL alone. A Phase II trial also shows the efficacy of Erbitux plus CAMPTOSAR and infusional FOLFIRI in EGFR-expres...